ALIGOS THERAPEUTICS INC's ticker is ALGS and the CUSIP is 01626L105. A total of 52 filers reported holding ALIGOS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $221,829 | -24.0% | 296,959 | -1.2% | 0.00% | – |
| Q2 2023 | $291,748 | +8.5% | 300,463 | -2.3% | 0.00% | – |
| Q1 2023 | $268,843 | -8.2% | 307,601 | +0.0% | 0.00% | – |
| Q4 2022 | $292,968 | -48.5% | 307,449 | -40.6% | 0.00% | – |
| Q3 2022 | $569,000 | -10.5% | 517,559 | -1.5% | 0.00% | – |
| Q2 2022 | $636,000 | -81.5% | 525,556 | -67.2% | 0.00% | – |
| Q1 2022 | $3,444,000 | -81.8% | 1,601,018 | +0.2% | 0.00% | – |
| Q4 2021 | $18,971,000 | -1.3% | 1,598,303 | +28.9% | 0.00% | -100.0% |
| Q3 2021 | $19,227,000 | -13.0% | 1,239,562 | +14.3% | 0.00% | 0.0% |
| Q2 2021 | $22,099,000 | +39.7% | 1,084,044 | +55.8% | 0.00% | – |
| Q1 2021 | $15,824,000 | -13.9% | 695,878 | +4.7% | 0.00% | -100.0% |
| Q4 2020 | $18,376,000 | – | 664,607 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,320,381 | $47,301,000 | 15.67% |
| Pivotal bioVenture Partners Investment Advisor LLC | 876,548 | $17,873,000 | 7.04% |
| Vivo Capital, LLC | 3,547,030 | $72,306,000 | 3.13% |
| Novo Holdings A/S | 2,614,563 | $53,311,000 | 2.36% |
| ACUTA CAPITAL PARTNERS, LLC | 214,254 | $4,368,000 | 1.75% |
| Boxer Capital, LLC | 1,526,048 | $31,108,000 | 1.10% |
| VR Adviser, LLC | 408,377 | $8,325,000 | 1.01% |
| Cormorant Asset Management, LP | 905,467 | $18,458,000 | 0.63% |
| HHLR ADVISORS, LTD. | 2,165,064 | $44,135,000 | 0.45% |
| Logos Global Management LP | 212,785 | $4,339,000 | 0.36% |